Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial

Z. Bielcikova, J. Stursa, L. Krizova, L. Dong, J. Spacek, S. Hlousek, M. Vocka, K. Rohlenova, O. Bartosova, V. Cerny, T. Padrta, M. Pesta, P. Michalek, SS. Hubackova, K. Kolostova, E. Pospisilova, V. Bobek, P. Klezl, R. Zobalova, B. Endaya, J....

. 2023 ; 57 (-) : 101873. [pub] 20230223

Status not-indexed Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23010161

BACKGROUND: Mitochondria present an emerging target for cancer treatment. We have investigated the effect of mitochondrially targeted tamoxifen (MitoTam), a first-in-class anti-cancer agent, in patients with solid metastatic tumours. METHODS: MitoTam was tested in an open-label, single-centre (Department of Oncology, General Faculty Hospital, Charles University, Czech Republic), phase I/Ib trial in metastatic patients with various malignancies and terminated oncological therapies. In total, 75 patients were enrolled between May 23, 2018 and July 22, 2020. Phase I evaluated escalating doses of MitoTam in two therapeutic regimens using the 3 + 3 design to establish drug safety and maximum tolerated dose (MTD). In phase Ib, three dosing regimens were applied over 8 and 6 weeks to evaluate long-term toxicity of MitoTam as the primary objective and its anti-cancer effect as a secondary objective. This trial was registered with the European Medicines Agency under EudraCT 2017-004441-25. FINDINGS: In total, 37 patients were enrolled into phase I and 38 into phase Ib. In phase I, the initial application of MitoTam via peripheral vein indicated high risk of thrombophlebitis, which was avoided by central vein administration. The highest dose with acceptable side effects was 5.0 mg/kg. The prevailing adverse effects (AEs) in phase I were neutropenia (30%), anaemia (30%) and fever/hyperthermia (30%), and in phase Ib fever/hyperthermia (58%) together with anaemia (26%) and neutropenia (16%). Serious AEs were mostly related to thromboembolic (TE) complications that affected 5% and 13% of patients in phase I and Ib, respectively. The only statistically significant AE related to MitoTam treatment was anaemia in phase Ib (p = 0.004). Of the tested regimens weekly dosing with 3.0 mg/kg for 6 weeks afforded the best safety profile with almost all being grade 1 (G1) AEs. Altogether, five fatalities occurred during the study, two of them meeting criteria for Suspected Unexpected Serious Adverse Events Reporting (SUSAR) (G4 thrombocytopenia and G5 stroke). MitoTam showed benefit evaluated as clinical benefit rate (CBR) in 37% patients with the largest effect in renal cell carcinoma (RCC) where four out of six patients reached disease stabilisation (SD), one reached partial response (PR) so that in total, five out of six (83%) patients showed CBR. INTERPRETATION: In this study, the MTD was established as 5.0 mg/kg and the recommended dose of MitoTam as 3.0 mg/kg given once per week via central vein with recommended preventive anti-coagulation therapy. The prevailing toxicity included haematological AEs, hyperthermia/fever and TE complications. One fatal stroke and non-fatal G4 thrombocytopenia were recorded. MitoTam showed high efficacy against RCC. FUNDING: Smart Brain Ltd. TRANSLATION: For the Czech translation of the abstract see Supplementary Materials section.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010161
003      
CZ-PrNML
005      
20231121140003.0
007      
ta
008      
230707s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eclinm.2023.101873 $2 doi
035    __
$a (PubMed)37064512
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bielcikova, Zuzana $u Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
245    10
$a Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial / $c Z. Bielcikova, J. Stursa, L. Krizova, L. Dong, J. Spacek, S. Hlousek, M. Vocka, K. Rohlenova, O. Bartosova, V. Cerny, T. Padrta, M. Pesta, P. Michalek, SS. Hubackova, K. Kolostova, E. Pospisilova, V. Bobek, P. Klezl, R. Zobalova, B. Endaya, J. Rohlena, L. Petruzelka, L. Werner, J. Neuzil
520    9_
$a BACKGROUND: Mitochondria present an emerging target for cancer treatment. We have investigated the effect of mitochondrially targeted tamoxifen (MitoTam), a first-in-class anti-cancer agent, in patients with solid metastatic tumours. METHODS: MitoTam was tested in an open-label, single-centre (Department of Oncology, General Faculty Hospital, Charles University, Czech Republic), phase I/Ib trial in metastatic patients with various malignancies and terminated oncological therapies. In total, 75 patients were enrolled between May 23, 2018 and July 22, 2020. Phase I evaluated escalating doses of MitoTam in two therapeutic regimens using the 3 + 3 design to establish drug safety and maximum tolerated dose (MTD). In phase Ib, three dosing regimens were applied over 8 and 6 weeks to evaluate long-term toxicity of MitoTam as the primary objective and its anti-cancer effect as a secondary objective. This trial was registered with the European Medicines Agency under EudraCT 2017-004441-25. FINDINGS: In total, 37 patients were enrolled into phase I and 38 into phase Ib. In phase I, the initial application of MitoTam via peripheral vein indicated high risk of thrombophlebitis, which was avoided by central vein administration. The highest dose with acceptable side effects was 5.0 mg/kg. The prevailing adverse effects (AEs) in phase I were neutropenia (30%), anaemia (30%) and fever/hyperthermia (30%), and in phase Ib fever/hyperthermia (58%) together with anaemia (26%) and neutropenia (16%). Serious AEs were mostly related to thromboembolic (TE) complications that affected 5% and 13% of patients in phase I and Ib, respectively. The only statistically significant AE related to MitoTam treatment was anaemia in phase Ib (p = 0.004). Of the tested regimens weekly dosing with 3.0 mg/kg for 6 weeks afforded the best safety profile with almost all being grade 1 (G1) AEs. Altogether, five fatalities occurred during the study, two of them meeting criteria for Suspected Unexpected Serious Adverse Events Reporting (SUSAR) (G4 thrombocytopenia and G5 stroke). MitoTam showed benefit evaluated as clinical benefit rate (CBR) in 37% patients with the largest effect in renal cell carcinoma (RCC) where four out of six patients reached disease stabilisation (SD), one reached partial response (PR) so that in total, five out of six (83%) patients showed CBR. INTERPRETATION: In this study, the MTD was established as 5.0 mg/kg and the recommended dose of MitoTam as 3.0 mg/kg given once per week via central vein with recommended preventive anti-coagulation therapy. The prevailing toxicity included haematological AEs, hyperthermia/fever and TE complications. One fatal stroke and non-fatal G4 thrombocytopenia were recorded. MitoTam showed high efficacy against RCC. FUNDING: Smart Brain Ltd. TRANSLATION: For the Czech translation of the abstract see Supplementary Materials section.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stursa, Jan $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
700    1_
$a Krizova, Ludmila $u Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Dong, Lanfeng $u School of Pharmacy and Medical Science, Griffith University, Southport, Qld 4222, Australia
700    1_
$a Spacek, Jan $u Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Hlousek, Stanislav $u Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Vocka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Rohlenova, Katerina $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
700    1_
$a Bartosova, Olga $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Cerny, Vladimir $u Department of Radiodiagnostics, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Padrta, Tomas $u Department of Radiodiagnostics, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Pesta, Michal $u Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague 121 06, Czech Republic
700    1_
$a Michalek, Pavel $u Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Hubackova, Sona Stemberkova $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague 4 140 21, Czech Republic
700    1_
$a Kolostova, Katarina $u Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
700    1_
$a Pospisilova, Eliska $u Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
700    1_
$a Bobek, Vladimir $u Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
700    1_
$a Klezl, Peter $u Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic $u Urology Clinic, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
700    1_
$a Zobalová, Renata $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic $7 xx0310352
700    1_
$a Endaya, Berwini $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic $u Department of Pediatrics and Inherited Metabolic Diseases, First Faculty of Medicine, Charles University, Prague 2 128 08, Czech Republic
700    1_
$a Rohlena, Jakub $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
700    1_
$a Petruzelka, Lubos $u Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
700    1_
$a Werner, Lukas $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
700    1_
$a Neuzil, Jiri $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic $u School of Pharmacy and Medical Science, Griffith University, Southport, Qld 4222, Australia $u Department of Pediatrics and Inherited Metabolic Diseases, First Faculty of Medicine, Charles University, Prague 2 128 08, Czech Republic $u Department of Physiology, Faculty of Science, Charles University, Prague 2 128 00, Czech Republic
773    0_
$w MED00200566 $t EClinicalMedicine $x 2589-5370 $g Roč. 57, č. - (2023), s. 101873
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37064512 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20231121140000 $b ABA008
999    __
$a ok $b bmc $g 1958660 $s 1196425
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 57 $c - $d 101873 $e 20230223 $i 2589-5370 $m EClinicalMedicine $n EClinicalMedicine $x MED00200566
LZP    __
$a Pubmed-20230707

Find record

Citation metrics

Archiving options